Identification of FDA-approved drugs targeting breast cancer stem cells along with biomarkers of sensitivity

Scientific Reports

Volumn 3, Issue , 2013, Pages

  Bhat Nakshatri, Poornima ^a   Goswami, Chirayu P ^a   Badve, Sunil ^a   Sledge, George W ^a   Nakshatri, Harikrishna ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; RETINOIC ACID; TUMOR MARKER;

ARTICLE; BREAST TUMOR; CANCER STEM CELL; DRUG APPROVAL; DRUG EFFECT; FOOD AND DRUG ADMINISTRATION; GENE EXPRESSION PROFILING; HUMAN; METABOLISM; METHODOLOGY; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; UNITED STATES; BREAST NEOPLASMS; DRUG EFFECTS; PROCEDURES;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DRUG APPROVAL; GENE EXPRESSION PROFILING; HUMANS; NEOPLASTIC STEM CELLS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; TRETINOIN; TUMOR MARKERS, BIOLOGICAL; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84883423984     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep02530     Document Type: Article

References (57)

1. Badve, S. & Nakshatri, H. Breast-cancer stem cells-beyond semantics. Lancet Oncol 13, e43-8 (2012).
2. Floor, S., van Staveren, W. C., Larsimont, D., Dumont, J. E. & Maenhaut, C. Cancer cells in epithelial-to-mesenchymal transition and tumor-propagatingcancer stem cells: distinct, overlapping or same populations. Oncogene 30, 4609-21 (2011).
3. Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J. & Clarke, M. F. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 100, 3983-8 (2003). (Pubitemid 36418143)
4. Ginestier, C. et al. ALDH1 Is a Marker of Normal and Malignant Human Mammary Stem Cells and a Predictor of Poor Clinical Outcome. Cell Stem Cell 1, 555-567 (2007). (Pubitemid 350056407)
5. Pece, S. et al. Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. Cell 140, 62-73 (2010).
6. Kim, J. et al. Tumor initiating but differentiated luminal-like breast cancer cells are highly invasive in the absence of basal-like activity. Proc Natl Acad Sci U S A 109, 6124-9 (2012).
7. Battula, V. L. et al. Ganglioside GD2 identifies breast cancer stem cells and promotes tumorigenesis. J Clin Invest 122, 2066-78 (2012).
8. Sachlos, E. et al. Identification of Drugs Including a Dopamine Receptor Antagonist that Selectively Target Cancer Stem Cells. Cell 149, 1284-97 (2012).
9. Horwitz, K. B., Dye, W. W., Harrell, J. C., Kabos, P. & Sartorius, C. A. Rare steroid receptor-negative basal-like tumorigenic cells in luminal subtype human breast cancer xenografts. Proc Natl Acad Sci U S A 105, 5774-9 (2008). (Pubitemid 351758448)
10. Li, X. et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 100, 672-9 (2008).
11. Creighton, C. J. et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A 106, 13820-5 (2009).
12. Cordenonsi, M. et al. The Hippo Transducer TAZ Confers Cancer Stem Cell- Related Traits on Breast Cancer Cells. Cell 147, 759-72 (2011).
13. Sorlie, T. et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98, 10869-74 (2001). (Pubitemid 32878711)
14. Hennessy, B. T. et al. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res 69, 4116-24 (2009).
15. Lehmann, B. D. et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121, 2750-67 (2011).
16. Gupta, P. B. et al. Identification of selective inhibitors of cancer stem cells by highthroughput screening. Cell 138, 645-59 (2009).
17. Singh, J. K. et al. Targeting CXCR1/2 significantly reduces breast cancer stem cell activity and increases the efficacy of inhibiting HER2 via HER2-dependent and -independent mechanisms. Clin Cancer Res 19, 643-56 (2013).
18. Lamb, J. et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313, 1929-35 (2006). (Pubitemid 44497995)
19. Sirota, M. et al. Discovery and preclinical validation of drug indications using compendia of public gene expression data. Sci Transl Med 3, 96ra77 (2011).
20. Bhat-Nakshatri, P. et al. SLUG/SNAI2 and tumor necrosis factor generate breast cells with CD441/CD242 phenotype. BMC Cancer 10, 411 (2010).
21. Liu, R. et al. The prognostic role of a gene signature from tumorigenic breastcancer cells. N Engl J Med 356, 217-26 (2007). (Pubitemid 46143225)
22. Shipitsin,M. et al.Molecular definition of breast tumor heterogeneity. Cancer Cell 11, 259-73 (2007). (Pubitemid 46349843)
23. Scaffidi, P. & Misteli, T. In vitro generation of human cells with cancer stem cell properties. Nat Cell Biol 13, 1051-61 (2011).
24. Petrie, K., Zelent, A. & Waxman, S. Differentiation therapy of acute myeloid leukemia: past, present and future. Curr Opin Hematol 16, 84-91 (2009).
25. Uray, I. P. & Brown, P.H. Chemoprevention of hormone receptor-negative breast cancer: new approaches needed. Recent Results Cancer Res 188, 147-62 (2011).
26. Fan, M. et al. Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant. Cancer Res 66, 11954-66 (2006). (Pubitemid 46094209)
27. Kao, J. et al. Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery. PLoS One 4, e6146 (2009).
28. Kippin, T. E.,Martens, D. J. & van der Kooy, D. p21 loss compromises the relative quiescence of forebrain stem cell proliferation leading to exhaustion of their proliferation capacity. Genes Dev 19, 756-67 (2005). (Pubitemid 40395086)
29. Andreu-Agullo, C.,Morante-Redolat, J. M., Delgado, A. C. & Farinas, I. Vascular niche factor PEDF modulates Notch-dependent stemness in the adult subependymal zone. Nat Neurosci 12, 1514-23 (2009).
30. Mani, S. A. et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133, 704-15 (2008). (Pubitemid 351636299)
31. Sheridan, C. et al. CD441/CD242 breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res 8, R59 (2006).
32. Leis, O. et al. Sox2 expression in breast tumours and activation in breast cancer stem cells. Oncogene 31, 1354-65 (2012).
33. Del Vecchio, C. A. et al. Epidermal Growth Factor Receptor Variant III Contributes to Cancer Stem Cell Phenotypes in Invasive Breast Carcinoma. Cancer Res (2012).
34. Gyorffy, B. et al. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat (2009).
35. Sarkar, A. & Hochedlinger, K. The sox family of transcription factors: versatile regulators of stem and progenitor cell fate. Cell Stem Cell 12, 15-30 (2013).
36. Kuzmichev, A. N. et al. Sox2 acts through Sox21 to regulate transcription in pluripotent and differentiated cells. Curr Biol 22, 1705-10 (2012).
37. Sherwood, R. I., Chen, T. Y. & Melton, D. A. Transcriptional dynamics of endodermal organ formation. Dev Dyn 238, 29-42 (2009).
38. Fan, Z., Li, J., Dong, B. & Huang, X. Expression of Cdx2 and hepatocyte antigen in gastric carcinoma: correlation with histologic type and implications for prognosis. Clin Cancer Res 11, 6162-70 (2005). (Pubitemid 41262943)
39. Huang, L. P., Yu, Y. H., Sheng, C. & Wang, S. H. Up-regulation of cadherin 17 and down-regulation of homeodomain protein CDX2 correlate with tumor progression and unfavorable prognosis in epithelial ovarian cancer. Int J Gynecol Cancer 22, 1170-6 (2012).
40. Matsumoto, K. et al. Cdx2 expression in pancreatic tumors: Relationship with prognosis of invasive ductal carcinomas. Oncol Rep 12, 1239-43 (2004).
41. Koboldt, D. C. et al.Comprehensive molecular portraits of human breast tumours. Nature (2012).
42. van?t Veer, L. J. et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415, 530-6 (2002).
43. Li, Y. et al. Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer. Nat Med 16, 214-8 (2010).
44. Klinakis, A. et al. Igf1r as a therapeutic target in amouse model of basal-like breast cancer. Proc Natl Acad Sci U S A 106, 2359-64 (2009).
45. Bhola, N. E. et al. TGF-beta inhibition enhances chemotherapy action against triple-negative breast cancer. J Clin Invest 123, 1348-58 (2013).
46. Bryan, M. et al. A pilot phase II trial of all-trans retinoic acid (Vesanoid) and paclitaxel (Taxol) in patients with recurrent or metastatic breast cancer. Invest New Drugs 29, 1482-7 (2011).
47. Sun, C. et al. Sox2 expression predicts poor survival of hepatocellular carcinoma patients and it promotes liver cancer cell invasion by activating Slug. Med Oncol 30, 503 (2013).
48. Proia, T. A. et al. Genetic predisposition directs breast cancer phenotype by dictating progenitor cell fate. Cell Stem Cell 8, 149-63 (2011).
49. Hu, Q. et al. The EGF receptor-sox2-EGF receptor feedback loop positively regulates the self-renewal of neural precursor cells. Stem Cells 28, 279-86 (2010).
50. Gupta, S. et al.Molecular Determinants of Retinoic Acid Sensitivity in Pancreatic Cancer. Clin Cancer Res (2011).
51. Schug, T. T. et al. Overcoming retinoic acid-resistance of mammary carcinomas by diverting retinoic acid from PPARbeta/delta to RAR. Proc Natl Acad Sci U S A 105, 7546-51 (2008). (Pubitemid 351830055)
52. Schug, T. T., Berry, D. C., Shaw, N. S., Travis, S. N. & Noy, N. Opposing effects of retinoic acid on cell growth result from alternate activation of two different nuclear receptors. Cell 129, 723-33 (2007). (Pubitemid 46802374)
53. Quinlan, M. P., Quatela, S. E., Philips, M. R.& Settleman, J.Activated Kras, but not Hras or Nras, may initiate tumors of endodermal origin via stem cell expansion. Mol Cell Biol 28, 2659-74 (2008). (Pubitemid 351542366)
54. Neve, R. M. et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10, 515-27 (2006). (Pubitemid 44854747)
55. Ginestier, C. et al. Retinoid signaling regulates breast cancer stem cell differentiation. Cell Cycle 8, 3297-302 (2009).
56. Papi, A. et al. Nuclear receptors agonists exert opposing effects on the inflammation dependent survival of breast cancer stem cells. Cell Death Differ (2012).
57. Patel, N. M. et al. Paclitaxel sensitivity of breast cancer cells with constitutively active NF-kappaB is enhanced by IkappaBalpha super-repressor and parthenolide. Oncogene 19, 4159-69 (2000).s